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ABSTRACT
Objectives: To quantify the uncertainty in the cost-
effectiveness of lifestyle intervention versus standard care in
overweight and obese people in Switzerland and to determine
if further research is necessary based on current information.
There has been an increasing interest in using value of infor-
mation analysis in medical decision-making to quantify the
uncertainty in decision-making, and to identify the need for
further research.
Methods: Value of information analysis was applied on a
probabilistic cost-effectiveness model to evaluate the uncer-
tainty by calculating the patient expected value of perfect
information (EVPI), population EVPI, and partial EVPI. The
costs were expressed in Swiss Francs (CHF), price year 2006.
Results: Overall, the EVPI was higher in overweight than in
obese people. The maximum population EVPI was CHF 6.8
million in overweight people and CHF 3.2 million in moder-
ate obese people, representing the upper limit on costs
associated with decision uncertainty. The partial EVPI esti-
mated a higher uncertainty in the model parameters such as
utilities, body mass index, cardiovascular risk factors, and
systolic blood pressure in overweight and moderate obese
subjects.
Conclusions: The EVPI analysis indicates that there is some
uncertainty regarding the choice between lifestyle interven-
tion and standard care. The parameter EVPI suggests that if
further research is commissioned, this should focus on the
effectiveness of lifestyle intervention on cardiovascular risk
factors and utilities.
Keywords: cost-effectiveness model, obesity, overweight,
Switzerland, value of information.
Introduction
The increasing prevalence of obesity worldwide under-
lines the pressing need for ﬁnding effective inter-
ventions to tackle the disease and its economic
consequences. In Switzerland, overweight and obesity
account for 37.1% of the population aged more than
15 years [1]. Obesity is associated with a high risk of
morbidity, mortality, as well as reduced life expectancy
[2]. The economic burden of obesity is substantial.
In Switzerland, obesity-related expenditures are esti-
mated to have a cost range approximately between
CHF 2691 million and CHF 3229 million, represent-
ing 2.3% to 3.5% of total health-care expenditures
[3].
The increasing burden on the budget of the Swiss
health-care providers resulted in considerable interest
in assessing existing treatments for their clinical effec-
tiveness and cost-effectiveness. A wide variety of treat-
ments for obesity are available including diet, physical
exercise, behavioral modiﬁcation, pharmacological
treatment, and surgery. Among several treatment
options, lifestyle intervention, including dietary coun-
seling and physical exercise, has been documented to
lead safely to improvements in metabolic abnormali-
ties such as increased body weight, dyslipidemia,
elevated blood pressure, and glucose control that are
linked to the development of obesity, diabetes, and
cardiovascular disease [4].
A decision-analytic model was developed to assess
the cost-effectiveness of lifestyle intervention in over-
weight and obese people in Switzerland [5]. Decision-
analytic models are extensively used in formal
decision-making process [6]. One of the requirements
for the decision-making is that uncertainty in adopting
a decision based on cost-effectiveness must be appro-
priately characterized and quantiﬁed because this
affects the value and the interpretation of the model
output. Many guidelines for cost-effectiveness analysis
recommend probabilistic sensitivity analysis to assess
uncertainty associated with the model parameters [7].
Value of information analysis has been suggested as a
natural methodological extension of the probabilistic
sensitivity analysis [8]. The analysis quantiﬁes the
uncertainty by establishing the value of acquiring
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additional information to inform decision-making. The
use of value of information analysis has been recently
encouraged in decision-analytic models [9–13].
The aim of the present study was to apply the value
of information analysis to assess the uncertainty in the
cost-effectiveness of lifestyle intervention in over-
weight and obese people in Switzerland and to deter-
mine if further research is necessary based on current
information.
Methods
Cost-Effectiveness Model
A probabilistic cost-effectiveness model based on
Markov process was developed to compare the effect
of lifestyle intervention with standard care in over-
weight and obese subjects. Seven health states were
modeled: “normal,” if subjects are overweight or
obese but free of complications, “hypertension,”
“hypercholesterolemia,” “type 2 diabetes,” “stroke,”
“coronary heart disease,” and “death.” A representa-
tion of the Markov model is presented in Figure 1.
Subjects enter the model in the normal health state.
Three characteristics are selected: starting age, starting
body mass index (the weight of the body in kilograms
divided by the square of its height in meters; BMI), and
sex. Based on BMI subjects are classiﬁed as overweight
if they have a BMI between 25 and 29.9 or obese if
they have a BMI of 30 or more. The cycle length is
1 year. At the end of each year, proportions of subjects
can move from one disease state to another or stay in
the same disease state. The transition probabilities
between cycles are based on the disease progression
with age, sex, BMI, and cycle number. We assumed
that all subjects developing hypertension, diabetes, and
hypercholesterolemia are diagnosed and treated. Sub-
jects remain in those states once they have entered,
unless they develop cardiovascular disease or die. The
possibility of having concomitant diabetes, hyperten-
sion, and hypercholesterolemia was not incorporated
into the model. One reason for excluding the correla-
tion between the existing comorbidities is the absence
of prevalence data for Swiss population. This assump-
tion is most probably underestimating the burden
associated with obesity-related comorbidities.
Subjects entering the model had a minimum age of
25 years and a maximum of 85 years; therefore, the
model runs for a period of 60 years from the age of
25 years, that is, when a subject enters the model at the
age of 60 years, themodel will run until he/shewill have
the age of 85 years. The reason for setting the age limit
is based on the average life expectancy in Switzerland
of 77.3 years for men and 82.8 for women [14]. We
considered that any simulation after the age of 85 years
would overestimate the costs and the effects.
A hypothetical cohort of 10,000 overweight or
obese subjects received a lifestyle intervention or stan-
dard care intervention for a period of 3 years. Lifestyle
intervention consisted of regular physical activity and
healthy eating, including diets rich in fruits and veg-
etables. Lifestyle intervention group members attended
dietitian sessions and supervised exercise sessions
during the ﬁrst 3 years. Standard care in overweight
people consisted in no intervention whereas in obese
people consisted in basic dietary counseling and physi-
cal exercise sessions (see cost description). Treatment
effect was modeled as a reduction in BMI, systolic
blood pressure, total cholesterol, and high-density
lipoprotein cholesterol based on data obtained in
3-year active treatment. It was assumed that the effect
of lifestyle intervention on cardiovascular risk factors
and weight loss is maintained up to 6 years, thereafter
subjects start to regain weight linearly for a period of
4 years, that is, after 10 years weight loss went back to
the initial weight. This is in line with the assumption
used in the economic evaluations of weight loss
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Figure 1 Markov model diagram.
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medication [15,16] and is based on observations from
clinical trials [17].
We estimated our model using data from a variety
of secondary sources. A summary of the data input is
presented in Table 1. The correlation between BMI
and annual risk of developing hypertension, diabetes,
and hypercholesterolemia was calculated based on two
large epidemiological studies: the Nurses Health Study
and the Health Professional Follow-up Study [18].
Intermediate values of BMI have been interpolated
using polynomial function. The risk of complications
had been adjusted according to age, sex, and preva-
lence of hypertension, diabetes, and hypercholester-
olemia based on the information provided by the Swiss
health survey [1]. The mean BMI by age and sex of the
Swiss population was obtained from published litera-
ture [14,19].
The risk of developing coronary heart disease and
stroke from “normal,” “hypertension,” “diabetes,”
and “hypercholesterolemia” health states were based
on a risk equation from the Framingham cohort study
[20]. The risk factors were age, sex, systolic blood
pressure, total cholesterol, high-density lipoprotein
cholesterol, presence of diabetes, and smoking status.
Data on systolic blood pressure, total cholesterol, and
high-density lipoprotein of the Swiss population were
obtained from literature [19]. The mean systolic blood
pressure increased with age in both men and women,
rising from 127 mmHg in men aged 25 to 35 years to
145 mmHg in men aged 75 years or more, and from
115 mmHg to 144 mmHg in women. The mean blood
cholesterol levels increased with age with a slight
decrease in the oldest age group.
Mortality rates of overweight and obese subjects in
the normal health state were assumed to be equivalent
to those observed in the general population although
there are studies that explored the relationship
between BMI and the risk of death [21,22]. Obesity
and overweight in adults are found to be associated
with large decreases in life expectancy and increases
in early mortality. Nevertheless, we decided not to
include these increased mortality risks because there is
a danger of double counting if the elevated mortality
risks are combined with associated complication mor-
tality rates. Age- and sex-speciﬁc mortality data were
obtained from the Swiss Federal Statistical Ofﬁce:
overall mortality data and disease speciﬁc according to
the International Classiﬁcation of Diseases (ICD-10
codes): I10–I15 Hypertensive disease, I20–I25 Ische-
mic heart disease, I60–I69 Cerebrovascular disease,
and E10–E14 Diabetes mellitus [23]. The yearly pro-
bability of developing diabetes, hypertension, coro-
nary heart disease, and stroke were obtained from the
actual number of deaths and disease prevalence rates
in Switzerland [1].
Data on the effectiveness of lifestyle intervention
was obtained using meta-analysis technique [24] of the
randomized controlled trials performed in overweight
and obese people. The meta-analysis combined the
long-term effects of lifestyle intervention on weight
and cardiovascular risk factors in overweight and
obese people from several studies. The lifestyle inter-
Table 1 Cost-effectiveness model data input
Parameter name Value Unit Distribution Source
BMI overweight* -1.11 kg/m2† Normal (95% CI -1.56 to -0.66) Meta-analysis
BMI obese* -1.33 kg/m2† Normal (95% CI -3.28 to -0.89) Meta-analysis
Systolic blood pressure overweight* -2.08 mmHg Normal (95% CI -3.28 to -0.89) Meta-analysis
Systolic blood pressure obese* -2.78 mmHg Normal (95% CI -4.38 to -1.18) Meta-analysis
Total cholesterol overweight* -0.26 mmol/L Normal (95% CI -0.41 to -0.12) Meta-analysis
Total cholesterol obese* -0.14 mmol/L Normal (95% CI -0.24 to 0.03) Meta-analysis
High-density lipoprotein overweight* 0.01 mmol/L Normal (95% CI -0.02 to 0.04) Meta-analysis
High-density lipoprotein obese* 0.04 mmol/L Normal (95% CI 0.01 to 0.08) Meta-analysis
Mortality probability Depending on age, complication Not applicable [23]
Utilities overweight/obesity Depending on age, BMI Beta (alpha, beta) [25]
Disutility due to obesity complications Depending on age, BMI, complication Beta (alpha, beta) [27]
Utility gain due to 1 unit decrease
in BMI
Depending on age, BMI, complication Beta (alpha, beta) [26]
Cost hypertension† 1,653 CHF Gamma (alpha 262, beta 6) [3]
Cost diabetes† 2,890 CHF Gamma (alpha 357 beta 8) [36]
Cost hypercholesterolemia† 1,245 CHF Gamma (alpha 149, beta 8) [3]
Cost stroke† 11,459 CHF Gamma (alpha 81, beta 142) [36]
Cost coronary heart disease† 6,054 CHF Gamma (alpha 67, beta 94) [3]
Cost lifestyle overweight/obesity year 1† 602 CHF Normal (95% CI 700 to 500) [28]
Cost lifestyle overweight/obesity year 2,
year 3†
333 CHF Normal (95% CI 400 to 200) [28]
Cost standard care obesity year 1† 269 CHF Normal (95% CI 400 to 200) [28]
Cost standard care obesity year 2, year 3† 102 CHF Normal (95% CI 150 to 90) [28]
*Incremental effect = Lifestyle intervention - Standard care.
†Cost per person per year.
BMI, body mass index; CHF, Swiss Francs year 2006; CI, conﬁdence interval.
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vention in all evaluated studies consisted in dietary
counseling and physical exercise sessions and lasted
from 1 to 6 years with an average follow-up time of
3 years. The summary outcome measure calculated
was the difference in means between lifestyle interven-
tion and standard care. Effects were combined using a
random effects model (Table 1).
Utility score represent the strength of patient pref-
erences for their own health on a scale from 0.0 (death)
to 1.0 (perfect health). Three published sources of
utilities were used: utilities for overweight and obese
people [25], utilities changes due to decreases in BMI
[26], and utilities associated with the complications of
obesity [27].
The data on resources used by patients receiving
lifestyle intervention or standard care were obtained
from the Finnish Diabetes Prevention Study [28] and
adapted for Switzerland. In the lifestyle intervention
group seven dietitian visits were assumed in the ﬁrst
year, and four visits per year thereafter. Based on the
unit cost of the health care calculated for Switzerland,
the dietician cost per visit was estimated at CHF 64
[29]. The same price was assumed for physical exercise
which was done in group sessions of 20 people for
1 hour. The group attended four sessions per month in
the ﬁrst year and two sessions per month during the
subsequent year. The total estimated cost of lifestyle
intervention was CHF 602 per person in the ﬁrst year
and CHF 333 per person per subsequent year. In the
standard intervention group, costs were assumed zero
in overweight people. For obese subjects the standard
care intervention consisted in three dietitian visits in
the ﬁrst year and one visit per year thereafter, and the
equivalent of two exercise sessions per month in the
ﬁrst year and one session per month during the subse-
quent year. The obesity medication costs were not
taken into consideration in the standard therapy of
obesity. Thus, a conservative estimate was preferred.
The total estimated cost of standard care intervention
in obese subjects was CHF 269 per person in the ﬁrst
year and CHF 102 per person per subsequent year.
The costs of obesity complications were obtained
from published literature and adjusted to 2006 Swiss
Francs (CHF) prices using the consumer price index
[30]. A top-down method using a prevalence approach
has been used to estimate the direct and indirect costs
of obesity complications.
Future costs and effects are presented undiscounted
and discounted at 3% rate; that is, a discount rate of
3% was applied to costs and utilities over the lifetime
of an individual patient in the cost-effectiveness model.
We evaluated the cost-effectiveness of lifestyle inter-
vention versus standard care intervention using a cost-
utility analysis. The cost-effectiveness of interventions
was compared using the incremental costs (CHF),
the incremental effects (quality-adjusted life-year
[QALY]), and the cost-effectiveness ratio (CHF/
QALY). In order to assess the effect of lifestyle inter-
vention in overweight and obese subjects, we deﬁned
two groups of people that were followed throughout
the analysis: overweight subjects (BMI = 28) and mod-
erate obese subjects (BMI = 33). A subgroup analysis
was performed in male and female subjects aged 30,
40, 50, and 60 years.
A probabilistic sensitivity analysis was performed
[31]. To reﬂect the uncertainty in themodel parameters,
they were incorporated in the model as probability
distribution. The cardiovascular risk factors data input
was characterized as normally distributed with stan-
dard deviations based on the meta-analysis results.
Utility scores were characterized as beta distributions
for two reasons: beta distribution takes values between
0 and 1, and it is a continuous distribution, which
is a desirable property for representing uncertainty.
Gamma distribution, which is constrained on the inter-
val 0 to positive inﬁnity, was used to characterize the
costs of obesity complications. Gamma distribution can
be highly skewed to reﬂect the skew often found in cost
data. We characterized the distribution of the costs of
interventions as normal with standard deviations equal
to the standard error, because it cannot take values less
than zero and it is positively skewed. Monte Carlo
simulation was used to propagate these distributions
through the model by recalculating the results over a
large number of simulations. The results of running the
probabilistic sensitivity analysis by randomly sampling
from the parameter distributions are presented on the
cost-effectiveness acceptability curve [32].
The cost-effectiveness analysis adopted the society
perspective. The model was developed using Microsoft
Excel (Microsoft Corporation, Redmond, WA).
Value of Information Analysis
Value of information analysis was undertaken for the
cost-effectiveness model by calculating the patient
expected value of perfect information (EVPI) [10],
population EVPI [11], and the partial EVPI associated
with model parameters [33]. The output from the
simulations was used to estimate the EVPI. The EVPI
for an individual patient was calculated as the differ-
ence between the expected value of the decision made
with perfect information and the decision made on the
basis of existing evidence [11]. The population EVPI
was obtained using patient EVPI applied to an esti-
mated annual incidence of overweight and obesity in
Switzerland [1]. A discount rate of 3% was applied to
the population size in the EVPI calculation. It was
assumed that the information on interventions would
be valuable for 10 years. We used a conservative
assumption considering that in a time of 10 years,
advancements in technology could inﬂuence the devel-
opment of new interventions able to better tackle
obesity and its complications. To determine which
parameters have the greatest value of information and
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require further research, we looked on following
parameters of the cost-effectiveness model: cardiovas-
cular risks (BMI, systolic blood pressure, total choles-
terol, high-density lipoprotein), utilities (overweight
and obese patient preferences), cost of interventions
(lifestyle intervention, standard care intervention), cost
of complications (diabetes, hypertension, hypercholes-
terolemia, coronary heart disease, stroke). The partial
EVPI calculated the value of information of the
remaining parameters of the model if we assumed
perfect information for the parameter of interest. The
partial EVPI for a parameter or group of parameters
was the difference between the expected value of the
decision made with perfect information and the deci-
sion made on the basis of existing evidence [11].
Results
Cost-Effectiveness Results
Table 2 presents the results of the cost-effectiveness
analysis based on current evidence. The lifestyle inter-
vention resulted in increased quality of life in over-
weight and obese subjects when results were
undiscounted and discounted at 3% rate. In over-
weight and obese people, the difference in quality of
life between lifestyle intervention and standard care
ranged from 0.19 to 0.41 QALYs (undiscounted) and
from 0.16 to 0.37 QALYs (discounted) per person per
year gained over lifetime, depending on sex and age
group. Compared with standard care intervention, the
average incremental cost of lifestyle intervention was
higher in overweight than in obese subjects, ranging
from CHF 510 to CHF 704 in female overweight
subjects and from CHF 402 to CHF 434 in male
overweight subjects, when results were discounted.
When results were undiscounted, the lifestyle inter-
vention dominated standard care being less costly and
more effective in female obese subjects aged 40 to
60 years and male obese subjects aged 30 to 60 years.
Figure 2 presents the probability that lifestyle inter-
vention is cost-effective for different threshold values
in overweight people. Lifestyle intervention had a
higher probability of being cost-effective in male sub-
jects compared to female subjects from the same age
Table 2 Probabilistic cost-effectiveness results
Age
(year)
Female Male
Undiscounted Discounted 3% Undiscounted Discounted 3%
Costs* QALY* ICER Costs* QALY* ICER Costs* QALY* ICER Costs* QALY* ICER
Overweight 30 427 0.19 2266 704 0.16 4358 104 0.24 437 434 0.20 2189
40 47 0.24 195 423 0.21 2037 164 0.26 626 438 0.22 1959
50 89 0.30 298 388 0.26 1516 187 0.30 616 408 0.26 1547
60 334 0.35 956 510 0.31 1660 263 0.37 707 402 0.32 1237
Obese 30 102 0.19 539 310 0.16 1922 -146 0.24 D† 105 0.21 508
40 -151 0.25 D† 100 0.21 469 -128 0.29 D† 98 0.25 400
50 -169 0.33 D† 55 0.28 195 -179 0.34 D† 40 0.30 133
60 -43 0.38 D† 116 0.34 342 -124 0.41 D† 27 0.37 73
*Difference between lifestyle intervention and standard care.
†D, lifestyle intervention dominates standard care intervention being more effective and less costly.
Costs are expressed in Swiss Francs (CHF) year 2006.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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group. If the decision-maker is willing to pay CHF
2000 for a unit of health gain, lifestyle intervention
will have a probability of being cost-effective ranging
from 48% to 91%, depending on sex and age group
with the exception of female and male overweight
subjects aged 30 years.
Figure 3 presents the probability that lifestyle inter-
vention is cost-effective for different threshold values
in moderate obese people. Lifestyle intervention had a
higher probability of being cost-effective in moderate
obese subjects compared to overweight subjects from
the same age group. Within moderate obese group,
lifestyle intervention had a higher probability of being
cost-effective in male subjects compared to female sub-
jects from the same age group. If the decision-maker is
willing to pay CHF 2000 for a unit of health gain,
lifestyle intervention will have a probability of being
cost-effective in moderate obese subjects ranging from
52% to 100% depending on sex and age group.
Value of Information Results
Table 3 presents the patient EVPI for overweight and
obese people. The patient EVPI reached a maximum at
the incremental cost-effectiveness ratio, that is, when
we are most uncertain about the decision based
on current information. A higher uncertainty was
observed in female overweight subjects aged 30 to
40 years and in female moderate obese subjects aged
30 years compared to other age groups.
Table 4 presents the population EVPI for over-
weight and obese people at alternative threshold
values. When results were undiscounted, the popula-
tion EVPI values ranged from zero to CHF 4.1 million
in overweight people and from zero to CHF 2.2
million in moderate obese people, depending on age,
sex, and threshold value. When results were dis-
counted at 3% rate, the population EVPI ranged from
zero to CHF 6.8 million in overweight people and
from zero to CHF 3.2 million in moderate obese
people, depending on age, sex, and threshold value.
A graphical representation of the population EVPI
in overweight people is presented for female subjects
(Fig. 4) and male subjects (Fig. 5). The population
EVPI in female overweight subjects was higher than in
male overweight subjects reﬂecting a higher uncer-
tainty. The subgroup analysis in overweight people
estimated a higher population EVPI in male and female
subjects aged 30 years compared to other age groups.
We examined the partial EVPI for six groups of
parameters (cardiovascular risks, utilities, cost of lif-
estyle intervention, cost of standard care intervention,
cost of complications, all costs) and nine individual
parameters (BMI, systolic blood pressure, total choles-
terol, high-density lipoprotein cholesterol, cost of
hypertension, cost of diabetes, cost of hypercholester-
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
CHF -              CHF 1,000         CHF 2,000         CHF 3,000         CHF 4,000         CHF 5,000         CHF 6,000
Value of health (maximum willingness to pay for additional QALY)
P
ro
ba
bi
lit
y 
co
st
-e
ffe
ct
iv
e
Female, Age 30 Female, Age 40
Female, Age 50 Female, Age 60
Male, Age 30 Male, Age 40
Male, Age 50 Male, Age 60
Figure 3 Cost-effectiveness acceptability
curves of lifestyle intervention in obese subjects
(discounted 3%). QALY, quality-adjusted
life-year.
Table 3 Patient expected value of perfect information (EVPI)
Age
(year)
Undiscounted
EVPI (CHF)
Discounted 3%
EVPI (CHF)
Overweight Female 30 133 198
40 101 103
50 83 76
60 68 48
Male 30 87 83
40 87 89
50 79 67
60 72 36
Obese Female 30 80 100
40 37 73
50 32 78
60 69 64
Male 30 38 78
40 40 63
50 30 72
60 42 77
CHF, Swiss Francs year 2006.
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olemia, cost of stroke, cost of coronary heart disease).
Overall, partial EVPI associated with the group of
parameters and the individual parameters was higher
in overweight subjects than in moderate obese subjects
depending on age and sex, when results were dis-
counted. In female overweight subjects, the partial
EVPI with the highest uncertainty was observed in the
utilities of subjects aged 30 years (CHF 4.7 million,
Table 4 Populations expected value of perfect information
Age
(year)
Yearly
incidence
Threshold value
CHF 0 CHF 1000 CHF 2000 CHF 5000
UD D UD D UD D UD D
Overweight Female 30 3,992 151,672 0 1,036,025 3,763 4,086,515 349,605 2,964,772 6,785,783
40 4,306 3,215,684 103,257 1,263,160 775,092 498,117 3,820,791 202,449 930,752
50 5,206 2,143,027 177,949 873,539 1,364,801 110,280 1,708,165 2,254 113,810
60 2,242 129,103 9,788 1,345,412 222,124 86,162 670,135 0 5,620
Male 30 6,391 2,931,215 83,508 2,497,611 689,783 900,063 4,239,067 361,361 2,116,957
40 3,513 1,104,473 20,491 1,724,479 408,452 465,928 2,721,024 73,454 351,013
50 5,719 1,254,367 122,617 1,817,459 1,142,732 204,300 1,833,086 11,229 37,324
60 662 84,714 20,710 178,891 203,992 6,951 46,084 0 8
Obese Female 30 1,825 679,929 16,727 911,252 354,991 538,373 1,618,853 496,053 995,249
40 1,325 409,488 409,662 61,116 427,004 22,427 144,496 20,462 65,683
50 2,269 748,764 1,123,705 38,155 252,393 4,051 31,075 0 1,672
60 3,512 2,168,665 953,722 58,058 318,340 2,519 12,670 0 0
Male 30 2,020 648,960 701,914 83,085 711,594 28,475 231,894 22,479 87,940
40 2,786 1,201,050 1,014,432 93,891 786,962 14,872 152,226 2,165 26,294
50 3,297 1,414,504 3,199,596 48,073 318,386 5,563 22,172 0 0
60 990 259,161 408,086 2,574 16,539 263 83 0 0
Results are presented undiscounted (UD) and discounted (D) at 3% rate.
CHF, Swiss Francs year 2006.
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Figure 4 Population expected value of perfect
information (EVPI) in female overweight sub-
jects aged 30 to 60 years (discounted 3%).
QALY, quality-adjusted life-year.
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Figure 5 Population expected value of perfect
information (EVPI) in male overweight subjects
aged 30 to 60 years (discounted 3%). QALY,
quality-adjusted life-year.
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Fig. 6), in the BMI of subjects aged 40 years (CHF 1.3
million), and in the cost of stroke of subjects aged
30 years (CHF 1.1 million). In male overweight sub-
jects, the partial EVPI with the highest uncertainty was
observed in the utilities of subjects aged 30 years (CHF
2.4 million) and in the BMI of subjects aged 50 years
(CHF 1.5 million). In female moderate obese subjects,
the partial EVPI with the highest uncertainty was
observed in the utilities of subjects aged 30 years (CHF
1.3 million) and in the BMI of subjects aged 60 years
(CHF 1.3 million, Fig. 7). In male moderate obese
subjects, the partial EVPI with the highest uncertainty
was observed in the cardiovascular risk factors of sub-
jects aged 50 years (CHF 3 million), in the BMI of
subjects aged 50 years (CHF 2.3 million), and in the
systolic blood pressure of subjects aged 50 years (CHF
1.7 million).
Discussion
Our study demonstrated the application of value of
information analysis to quantify the uncertainty. We
tried to address the following issues: to determine if the
selection of lifestyle intervention is optimal based on
the current information available; to assess if it is
worth collecting additional information to inform this
decision in the future; and to determine which param-
eters in the obesity cost-effectiveness model have the
greatest value of information and require further
research.
The cost-effectiveness results demonstrated that,
based on existing evidence, the lifestyle intervention
can be regarded as cost-effective only in certain situa-
tions depending on sex, age group, and threshold
value. When no discount was applied, the lifestyle
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Figure 6 Partial expected value of perfect
information (EVPI) in female overweight sub-
jects aged 30 to 60 years (discounted 3%).
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Figure 7 Partial expected value of perfect
information (EVPI) in female moderate obese
subjects aged 30 to 60 years (discounted 3%).
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intervention dominated standard care in moderate
obese people being less costly and more effective.
When a discount of 3% was applied, lifestyle interven-
tion was cost-effective at an incremental cost per
QALY ranging from 1237 to 4358 CHF/QALY in
overweight people and from 73 to 1922 CHF/QALY in
moderate obese people, depending on age and sex. A
recent economic review of nonpharmacological weight
loss treatments found that if weight loss, relative to
the observed trend, remains constant for 5 years post
intervention before returning to baseline, the cost per
QALY in the best performing nonpharmacological
studies ranges from 429 to 24566 CHF/QALY [34].
Our cost-effectiveness model assumed that lifestyle
intervention effect on weight and cardiovascular risk
factors lasts for 6 years based on the results obtained
from meta-analysis of 3-year randomized clinical trials
in overweight and obese people. This assumption is in
line with the extended follow-up of the Finnish Diabe-
tes Prevention Study which lasted 7 years and resulted
in sustained lifestyle changes and a reduction of dia-
betes incidence, which was maintained after the indi-
vidual lifestyle counseling stopped [35]. The study
reported a 43% reduction in the relative risk related to
the success in achieving the intervention goals of
weight loss, reduced intake of total and saturated fat,
increased intake of dietary ﬁber, and increased physical
activity.
The value of information analysis places a limit on
returns to further research. If the costs of the research
exceed the EVPI, then the proposed research is not
cost-effective [10]. In our analysis, the maximum
population EVPI was CHF 6.8 million in overweight
subjects and CHF 3.2 million in moderate obese sub-
jects. These values represent an upper limit on the costs
associated with the decision uncertainty. Therefore,
costs associated to proposed future research should
not exceed this amount if the research would be con-
sidered cost-effective.
The partial EVPI with the highest uncertainty was
observed in the utilities of male and female over-
weight subjects aged 30 years and female moderate
obese subjects aged 30 years. One possible explana-
tion could be that utilities used in the model were
obtained from the published literature [25]. Further
investigations are necessary to evaluate the over-
weight and obese patients’ preferences on weight loss
treatments in Switzerland. Further research is needed
to calculate the expected beneﬁts and the cost of
sample information to determine the optimal study
design such as follow-up time, sample size, and
patient allocation.
A higher partial EVPI was observed in the BMI of
female overweight subjects aged 40 years, male over-
weight subjects aged 50 years, female moderate obese
subjects aged 60 years, and male moderate obese sub-
jects aged 50 years. A higher uncertainty was observed
also in male moderate obese subjects aged 50 years in
parameters such as cardiovascular risk factors and sys-
tolic blood pressure. Therefore, further research on the
cardiovascular risk factors in overweight and obese
people in Switzerland is recommended.
Based on the results of our study, we identiﬁed
four factors that inﬂuence the uncertainty and
implicit the EVPI. The ﬁrst factor was the level of the
maximum willingness to pay for an additional unit
of health gain with lifestyle intervention. The EVPI
depended on the value of the maximum acceptable
threshold. This was due to the interaction between
the maximum acceptable threshold and the uncer-
tainty surrounding the decision. When the maximum
acceptable threshold was close to the incremental
cost-effectiveness ratio, then the uncertainty sur-
rounding the decision was maximized. The second
factor was the uncertainty surrounding the decision
to adopt the lifestyle intervention. The uncertainty
surrounding this decision was an important element
in the calculation of EVPI, with the EVPI increasing
with increased uncertainty. Therefore, when the un-
certainty surrounding a decision was low, the EVPI
was negligible; for example, in male obese subjects
aged 40 years the EVPI was CHF 63 when results
were discounted. The third factor was the size of the
eligible population. The size of the population eligible
for treatment had a direct impact on the population
level estimates of the EVPI. Where the population
was large, the scaled-up population values were
larger. For example, the population values of the
EVPI were larger for male overweight subjects aged
50 years than for male overweight subjects aged
60 years because of an increase incidence of male
overweight subjects aged 50 years. The fourth factor
that inﬂuenced the uncertainty and EVPI in our
model was represented by patient characteristics such
as age, sex, and BMI. Our analysis suggests that the
allocation of funds between lifestyle intervention and
standard care in the prevention and treatment of
obesity and future research will depend crucially on
these four factors.
Our study results are limited by several factors
related to the structure of the cost-effectiveness model
and the EVPI analysis. The model could be improved
by having access to additional Swiss-speciﬁc data. So
far, epidemiological data such as the correlation
between BMI and the risk of complications, obesity-
related mortality data, and changes in patient utility
have not been recorded speciﬁcally for Switzerland.
Further investigations should also take into account
other important complications of obesity such as
metabolic syndrome, colorectal cancer, gall bladder
disease, sleep apnea, and depression. Another limita-
tion of our study consists in the estimation of the
costs of obesity complications from secondary data
sources.
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Both probabilistic sensitivity analysis and param-
eter EVPI were computed using Monte Carlo methods.
Unfortunately, to obtain these measures accurately,
very large numbers of model evaluations are needed,
potentially millions. For computationally expensive
computer models, evaluating these measures may then
require lengthy computing times. Our model used
3000 simulations for the probabilistic sensitivity
analysis and 50 simulations for the partial EVPI. To
assess the validity of the study results, we performed
additional analyses for different age groups in both
sexes using 5000 simulations for the probabilistic sen-
sitivity analysis and 250 simulations for the partial
EVPI. The new results of the parameter EVPI showed
the existence of a slight overestimating bias in using
small numbers of Monte Carlo samples. Nevertheless,
the overall trend of the parameters presented in the
results section was maintained. Further theoretical
investigation of Monte Carlo bias in the context of
parameter EVPI would be useful.
Conclusion
In summary, we applied the value of information
analysis to evaluate the uncertainty in the cost-
effectiveness of lifestyle interventions in overweight
and obese people in Switzerland. The value of in-
formation analysis indicates that there is some
uncertainty regarding the choice between lifestyle
intervention and standard care intervention. The
extent of the uncertainty depends on the maximum
acceptable threshold, the uncertainty surrounding the
decision to adopt the lifestyle intervention, the size of
the eligible population, and patient characteristics. The
parameter EVPI suggests that if further research is
commissioned, this should focus on the effectiveness of
lifestyle intervention on the cardiovascular risk factors
and quality of life of the overweight and obese people
in Switzerland.
Source of ﬁnancial support: This study was funded by
the Swiss Federal Ofﬁce of Health (Bundesamtes für
Gesundheit).
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